Overview
Adamax is a synthetic nootropic peptide developed as a structurally modified analog of Semax — itself a synthetic heptapeptide derived from the ACTH(4-10) fragment of adrenocorticotropic hormone. Semax (Met-Glu-His-Phe-Pro-Gly-Pro) has been a registered medicine in Russia since 1994, where it is used clinically for stroke recovery, cognitive impairment, and neuroprotection. Adamax extends the Semax scaffold by incorporating an adamantane group at the N-terminus, a medicinal chemistry strategy designed to enhance CNS penetration, metabolic stability, and duration of action. The proposed mechanism centers on the well-characterized ability of Semax to rapidly upregulate brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in glial cells and hippocampal tissue. BDNF is one of the most important molecules in cognitive neuroscience — it promotes neuronal survival, synaptic p
Mechanism of Action
Adamax's proposed mechanism is inferred from its parent compound Semax, which has an extensively characterized research profile spanning 30+ years of Russian clinical and preclinical research. Semax's primary documented mechanism is rapid upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) in glial cells and hippocampal tissue. BDNF binds to TrkB receptors, activating intracellular signaling cascades (PI3K/Akt, MAPK/ERK) that promote neuronal survival, synaptic strengthening (long-term potentiation), dendritic growth, and neurogenesis in the hippocampus. NGF supports cholinergic neuron survival and is critical for memory consolidation in the basal forebrai
Research Evidence
- Parent compound Semax: rapidly upregulates BDNF and NGF mRNA in rat glial cultures within hours (Dolotov et al., 2006)
- Semax increases hippocampal BDNF and TrkB signaling after intranasal administration (Agapova et al., 2007)
- Adamantane modification strategy validated by CNS-active drugs amantadine and memantine (NMDA antagonists)
- Semax registered medicine in Russia since 1994 for stroke recovery and cognitive impairment
- Intranasal delivery route (nasal spray) provides direct olfactory pathway to CNS, bypassing blood-brain barrier
Bottom line: Adamax is a plausible next-generation Semax derivative with a well-reasoned structural modification. However, it is a supplier-defined compound with no peer-reviewed studies characterizing it specifically. Its properties are inferred from Semax literature, not directly demonstrated. Treat it as a novel research compound requiring independent characterization.
Research Protocols & Dosage
Evidence-based research protocols, administration routes, and dosage considerations for Adamax are detailed in the full compound profile. See also: Dosage guide for Adamax.
Sourcing & Quality
Adamax is available from Purgo Labs with third-party COA verification and research-grade purity standards. View Adamax at Purgo Labs.